We at AOP Orphan are European pioneers in the field of rare diseases, researching, developing, producing, and distributing innovative solutions worldwide since 1996. Learn more about the company here.
We at AOP Orphan focus on rare diseases particularly in the areas of HematoOncology, Cardiology & Pulmonology, Neurology & Metabolic Disorders. Learn more about the indications, its symptoms, diagnosis, therapies and everyday life here.
Our strategic goal at AOP Orphan is to constantly deliver new treatment options for the patients with rare disease. Learn more about the current product portfolio and countries' availability here.
Agile, ambitious and aligned team members, mutual appreciation and commitment - this is what makes AOP Orphan a successful company and great place to work. Learn more about the company, open positions and everyday life at AOP Orphan here.
Active Ingredient Pitolisant
Wakix® is indicated in adults for the treatment of narcolepsy with or without cataplexy.
Wakix® 4.5mg, 18mg film-coated tablets
Bioprojet Pharma SAS is the MA-Holder and AOP Orphan has the distribution right.